• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺乳头状癌滤泡变体的分子特征及临床病理特征。ras突变的异常高发生率。

Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

作者信息

Zhu Zhaowen, Gandhi Manoj, Nikiforova Marina N, Fischer Andrew H, Nikiforov Yuri E

机构信息

Departments of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, 231 Albert Sabin Way, PO Box 670529, Cincinnati, OH 45267-0529, USA.

出版信息

Am J Clin Pathol. 2003 Jul;120(1):71-7. doi: 10.1309/ND8D-9LAJ-TRCT-G6QD.

DOI:10.1309/ND8D-9LAJ-TRCT-G6QD
PMID:12866375
Abstract

The follicular variant (FV) of papillary thyroid carcinoma is characterized by a follicular growth pattern and cytologic features of papillary carcinoma. ret/PTC rearrangements are common in classic papillary thyroid carcinoma (PTC) and PAX8-PPAR gamma and ras mutations in follicular thyroid carcinoma. Their prevalence in FV has not been established. We studied these genetic alterations and clinical-pathologic features in 30 FV cases and compared those with 46 non-FV papillary carcinomas. FV cases revealed 1 ret/PTC rearrangement (3%) and 13 ras mutations (43%). Non-FV cases harbored 13 ret/PTC (28%) (P = .006) and no ras mutations (P = .0002). No PAX8-PPAR gamma was found in either group. FV cases demonstrated a significantly higher prevalence of tumor encapsulation, angiovascular invasion, and poorly differentiated areas and a lower rate of lymph node metastases. These data indicate that the FV of papillary carcinoma has a distinct set of molecular alterations and is characterized by a high frequency of ras point mutations.

摘要

甲状腺乳头状癌的滤泡状变异型(FV)以滤泡状生长模式和乳头状癌的细胞学特征为特点。ret/PTC重排在经典甲状腺乳头状癌(PTC)中常见,而PAX8-PPARγ和ras突变在滤泡状甲状腺癌中常见。它们在FV中的发生率尚未确定。我们研究了30例FV病例中的这些基因改变和临床病理特征,并将其与46例非FV乳头状癌进行比较。FV病例显示1例ret/PTC重排(3%)和13例ras突变(43%)。非FV病例有13例ret/PTC(28%)(P = .006)且无ras突变(P = .0002)。两组均未发现PAX8-PPARγ。FV病例显示肿瘤包膜、血管侵犯和低分化区域的发生率显著更高,而淋巴结转移率更低。这些数据表明,乳头状癌的FV具有独特的分子改变组合,且以ras点突变的高频率为特征。

相似文献

1
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.甲状腺乳头状癌滤泡变体的分子特征及临床病理特征。ras突变的异常高发生率。
Am J Clin Pathol. 2003 Jul;120(1):71-7. doi: 10.1309/ND8D-9LAJ-TRCT-G6QD.
2
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.甲状腺肿瘤中的RAS点突变和PAX8-PPARγ重排:甲状腺滤泡癌中不同分子途径的证据
J Clin Endocrinol Metab. 2003 May;88(5):2318-26. doi: 10.1210/jc.2002-021907.
3
PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.PAX8-PPARγ重排在甲状腺乳头状癌滤泡变体中经常被检测到。
J Clin Endocrinol Metab. 2006 Jan;91(1):213-20. doi: 10.1210/jc.2005-1336. Epub 2005 Oct 11.
4
Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.PAX8-PPARγ1重排在滤泡状甲状腺癌和腺瘤中的表达。
J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52. doi: 10.1210/jcem.87.8.8756.
5
The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma.
Clin Endocrinol (Oxf). 2004 Aug;61(2):280-2. doi: 10.1111/j.1365-2265.2004.02061.x.
6
Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.17号染色体三体作为具有乳头状癌局灶特征的非侵袭性甲状腺结节亚组的标志物:62例细胞遗传学和分子分析及其与组织学结果的相关性
J Clin Endocrinol Metab. 2008 Jan;93(1):177-81. doi: 10.1210/jc.2007-0970. Epub 2007 Oct 23.
7
Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.韩国人群分化型甲状腺肿瘤中Gsα、ras、p53基因突变及ret/PTC重排的发生率
Clin Endocrinol (Oxf). 1998 Sep;49(3):317-23. doi: 10.1046/j.1365-2265.1998.00515.x.
8
Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.在高分化甲状腺滤泡性肿瘤的发生过程中,非整倍体和RAS突变是相互排斥的事件。
Clin Endocrinol (Oxf). 2007 Nov;67(5):706-11. doi: 10.1111/j.1365-2265.2007.02949.x. Epub 2007 Jul 25.
9
Simultaneous occurrence of PAX8-PPARg and RET-PTC3 rearrangements in a follicular variant of papillary thyroid carcinoma.甲状腺滤泡型乳头状癌中同时出现 PAX8-PPARg 和 RET-PTC3 重排。
Am J Surg Pathol. 2012 Sep;36(9):1415-20. doi: 10.1097/PAS.0b013e318264bdd6.
10
Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas.在滤泡状甲状腺癌和腺瘤中检测PAX8-PPARγ融合致癌基因。
J Clin Endocrinol Metab. 2003 Jan;88(1):354-7. doi: 10.1210/jc.2002-021020.

引用本文的文献

1
Alterations in gene expression associated with invasion of RAS-mutant thyroid tumors and their potential diagnostic and therapeutic utility.与RAS突变型甲状腺肿瘤侵袭相关的基因表达改变及其潜在的诊断和治疗价值。
Eur Thyroid J. 2025 Jun 10;14(3). doi: 10.1530/ETJ-25-0022. Print 2025 Jun 1.
2
Breast cancer histopathology, classification and clinical management: Current perspectives.乳腺癌组织病理学、分类及临床管理:当前观点
Bioinformation. 2024 Dec 31;20(12):2069-2079. doi: 10.6026/9732063002002069. eCollection 2024.
3
KRAS-SOS-1 Inhibition as New Pharmacological Target to Counteract Anaplastic Thyroid Carcinoma (ATC).
抑制KRAS-SOS-1作为对抗间变性甲状腺癌(ATC)的新药理学靶点。
Int J Mol Sci. 2025 Mar 13;26(6):2579. doi: 10.3390/ijms26062579.
4
New Horizons of Biomarkers in Metastatic Thyroid Cancer.转移性甲状腺癌生物标志物的新视野
J Cancer. 2025 Jan 1;16(1):241-264. doi: 10.7150/jca.101395. eCollection 2025.
5
The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors.术前分子检测在贝塞斯达Ⅴ级和贝塞斯达Ⅵ级甲状腺肿瘤管理中的价值。
Hormones (Athens). 2025 Mar;24(1):217-229. doi: 10.1007/s42000-024-00597-0. Epub 2024 Sep 3.
6
The Role of Inositols in Endocrine and Neuroendocrine Tumors.肌醇在内分泌和神经内分泌肿瘤中的作用。
Biomolecules. 2024 Aug 14;14(8):1004. doi: 10.3390/biom14081004.
7
Defining angioinvasion and lymphatic invasion in papillary thyroid carcinoma: morphological criteria, utility of D2-40/CD31/ERG immunohistochemistry and correlation with clinicopathological characteristics.定义甲状腺乳头状癌的血管侵犯和淋巴管侵犯:形态学标准、D2-40/CD31/ERG 免疫组化的应用及与临床病理特征的相关性。
Histopathology. 2024 Dec;85(6):950-958. doi: 10.1111/his.15285. Epub 2024 Jul 18.
8
Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review).鉴别甲状腺乳头状癌中BRAF V600E基因突变的鉴别诊断方法的比较效率(综述)
Exp Ther Med. 2024 Feb 20;27(4):149. doi: 10.3892/etm.2024.12437. eCollection 2024 Apr.
9
Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A review on Surgical Treatment.甲状腺乳头状癌的包膜内滤泡变体:手术治疗综述
Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):6384-6390. doi: 10.1007/s12070-022-03107-z. Epub 2022 Jul 23.
10
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.美国头颈部学会内分泌外科分会和国际甲状腺肿瘤学会共识声明:甲状腺癌的基因突变检测——定义晚期甲状腺癌及其靶向治疗。
Head Neck. 2022 Jun;44(6):1277-1300. doi: 10.1002/hed.27025. Epub 2022 Mar 11.